Nebulized and adjunctive pharmacotherapy for inhalation injury

Overview

Inhalation injury is a common and frequently overlooked companion of cutaneous burn, and it is one of the classic independent determinants of burn mortality alongside age, burn size, and resuscitation delay [1, 23]. It occurs in 10–30% of patients admitted to burn centers and increases mortality by a maximum of 20% over that predicted by age and extent of cutaneous burn alone ^[12]. Adding inhalation injury to a cutaneous burn raises fluid resuscitation requirements, the incidence of pulmonary complications, and overall mortality ^[44]. Smoke inhalation-associated acute lung injury contributes to roughly 30% of burn deaths ^[45].

The backbone of treatment is supportive: oxygen, airway protection, and lung-protective mechanical ventilation. Nebulized and systemic adjunctive pharmacotherapy is layered onto that backbone. The agents discussed here, heparin, N-acetylcysteine, bronchodilators, epinephrine, antithrombin, fibrinolytics, corticosteroids, antioxidants, and a long preclinical pipeline, are adjuncts, not substitutes for ventilatory support. The defining tension of the field is that decades of research have produced a strong mechanistic rationale and consistent large-animal data without a drug that definitively changes survival, a gap compounded by the absence of uniform diagnostic criteria [89, 90]. For at least one exposure class, white smoke, no effective pharmaceutical treatment has been developed ^[2]. This page covers the drugs; airway diagnosis, bronchoscopic grading, and ventilator strategy belong to the parent inhalation-injury topic.

Pathophysiologic rationale

Each drug class maps to a specific lesion. Understanding the lesion is the only way to read the evidence honestly, because the mechanism is usually far better supported than the clinical benefit.

The central lesion is the obstructive airway cast. Heat and chemical injury slough the tracheobronchial epithelium, which combines with a protein-rich exudate to form casts that occlude the airways ^[16]. Casts produced from sloughed cells, polymorphonuclear leukocytes, and mucus cause upper-airway obstruction and contribute to pulmonary failure ^[19]. In ovine models, more than 30% of both bronchi and bronchioles are obstructed by cast formation after smoke inhalation and pneumonia ^[11]. Fibrin casts inside the airways constitute a prominent element of the injury; the material residing in the tracheobronchial tree causes ventilation–perfusion mismatch, complicates mechanical ventilation, and provides a medium for bacterial growth ^[29]. This cast lesion is the direct rationale for nebulized heparin, tissue plasminogen activator, and antithrombin.

The cast biology is driven by an airway and pulmonary coagulopathy. Pulmonary coagulopathy is a hallmark of lung injury following inhalation trauma, with a procoagulant and antifibrinolytic shift in alveolar homeostasis [31, 89]. Antithrombin falls early: in a human cohort, 108 of 200 patients (54%) developed antithrombin deficiency during hospitalization, with risk rising with total body surface area and inhalation injury, and the deficient state peaking within the first five days ^[10]. Plasma antithrombin falls further when burn is added to inhalation ^[49]. This local coagulopathy is the bridge between casts and anticoagulant drugs, and motivates both nebulized and systemic antithrombin strategies.

A second lesion is bronchospasm with increased bronchial blood flow. The main pathophysiologic change after a subglottic inhalation injury is an increase in bronchial blood flow ^[16]. In humans and in the ovine combined-injury model, bronchospasm and acute airway obstruction contribute to progressive pulmonary insufficiency ^[25]. Acetylcholine contributes to the constrictive and luminal-obstructive response, which is the rationale for beta-2 agonists, the combined alpha/beta agonist epinephrine, and muscarinic antagonists ^[25]. Clinically, bronchospasm is the earliest stage of the injury, appearing 1 to 12 hours post-burn, before edema (6 to 72 hours) and bronchopneumonia (after 60 hours) ^[3].

A third lesion is oxidant and inflammatory injury. Lung lesions in inhalation injury result in part from oxygen free radicals released by marginating polymorphonuclear leukocytes, with peroxide and hydroxyl ions implicated in increased microvascular permeability and edema ^[5]. Reactive oxygen and nitrogen species play a central pathogenic role ^[89]. This is the rationale for antioxidant and anti-inflammatory adjuncts, including N-acetylcysteine (a glutathione precursor and mucolytic), tocopherols, and vitamin C. Surfactant deactivation is an additional documented factor that may promote late respiratory failure, providing the rationale for exogenous surfactant [92, 4].

Nebulized heparin

Nebulized unfractionated heparin is given for a local anticoagulant and anti-fibrin effect to reduce cast formation and airway obstruction, not for systemic anticoagulation ^[55]. Delivering the anticoagulant by nebulization rather than systemically is intended to raise local biological availability in the lung while lowering systemic bleeding risk, and across preclinical studies nebulized anticoagulants attenuate pulmonary coagulopathy and frequently inflammation ^[85]. The dominant human protocol is 10,000 units every 4 hours, alternating with N-acetylcysteine and albuterol; 5,000 units has also been studied, and a dose-comparison trial studied both 5,000 and 10,000-unit arms alternating with NAC [42, 91, 53].

The strongest human signal is on ventilation, not survival. In the HIHI retrospective cohort, patients receiving nebulized heparin had a statistically significant decrease in median duration of initial mechanical ventilation versus controls (7.0 vs 14.5 days; P = 0.044) and significantly more ventilator-free days in the first 28 days ^[27]. A 2025 randomized trial of early inhaled heparin (5,000 units) reported more ventilator-free days, faster weaning, more ICU-free days, and higher PaO2/FiO2 ^[56]. A dose-finding randomized trial found that heparin decreased lung-injury scores and ventilation duration but had no effect on ICU length of stay or mortality ^[53]. A 2026 randomized trial pairing scheduled bronchoscopy with alternating heparin and NAC reported lower unadjusted 28-day mortality and improved respiratory mechanics, but on multivariable Cox analysis only baseline severity predicted mortality, and the intervention showed a non-significant hazard trend (adjusted HR 0.66, 95% CI 0.36–1.23) ^[78].

Meta-analytic syntheses are mixed and carry methodologic warnings. A pooled mortality risk ratio for heparin of 0.32 was reported, but the authors judged the benefits may be severely biased by poor methodologic quality and concluded there is no strong evidence that heparin improves clinical outcomes in burn injury ^[80]. A human meta-analysis found heparin nebulization attenuated lung injury, shortened ventilation duration, and reduced mortality, but did not reduce pneumonia incidence or unplanned reintubation ^[37]. An animal-model meta-analysis found a lower death rate with heparin (RR 0.42, 95% CI 0.22–0.80) ^[38]. The cornerstone ovine data show heparin decreases tracheobronchial cast formation, improves oxygenation, minimizes barotrauma, and reduces pulmonary edema, although heparin does not reduce oxygen free-radical activity ^[9]. Several animal studies are negative for heparin alone: high-dose heparin failed to prevent lung dysfunction in combined smoke and sepsis, and aerosolized heparin alone did not significantly improve gas exchange unless combined with another agent [14, 30]. In an ovine model, nebulized heparin alone did not attenuate pulmonary dysfunction after severe smoke injury, whereas combining nebulized heparin with systemic lisofylline improved pulmonary function ^[88].

N-acetylcysteine and the heparin–NAC regimen

N-acetylcysteine is used as a mucolytic and antioxidant: nebulized NAC targets mucus casts, complementing heparin's action on fibrin casts ^[16]. Its antioxidant and surfactant effects are demonstrated in animal work, but NAC is almost never studied alone clinically in this setting; nearly all human data sit inside the heparin–NAC bundle ^[16].

That bundle is the de facto standard nebulized regimen: heparin alternating with NAC, often with albuterol, on a scheduled every-2-to-4-hour protocol. Its foundational positive result is pediatric: 47 children received 5,000 units heparin plus 20% NAC aerosolized every 4 hours for the first 7 days, with a significant decrease in reintubation, atelectasis, and mortality versus controls ^[21]. In ventilated adults, an aerosolized unfractionated heparin plus NAC plus albuterol regimen attenuated lung injury and ARDS progression after smoke inhalation ^[19]. An observational study found heparin was the only variable associated with reduced mechanical-ventilation duration, although the non-heparin group had a much higher mean burn size, a confounder that limits the inference ^[40].

Because the agents are co-administered on alternating schedules, no human study cleanly isolates a single component's effect; the honest framing is that the bundle has a signal while component attribution is weak. The negative evidence is load-bearing and is discussed under Outcomes and Safety. A 2025 retrospective study found the protocol did not improve outcomes for grade II or III injuries, with only 47.5% of patients receiving it, and called for large multicenter trials to determine true efficacy ^[73].

Bronchodilators

Inhalation injury produces bronchospasm, airway obstruction, and increased bronchial circulation, which is the rationale for beta-2 agonists and anticholinergics [89, 25]. In an ovine comparative study, continuous nebulized albuterol lowered peak and pause inspiratory pressures, decreased transvascular fluid flux, raised PaO2/FiO2, and reduced the lung wet-to-dry ratio and bronchial obstruction scores ^[13]. Human data are thinner: in fire-eaters, aerosolized salbutamol produced a statistically significant rise in nearly all spirometric variables, but only 63% (10 of 16) had a positive bronchodilation response ^[15]. Albuterol is the bronchodilator component in most standard nebulized protocols [19, 27].

The anticholinergic evidence is animal-only. In ovine inhalation injury, the muscarinic antagonist tiotropium attenuated rises in ventilatory pressures, pulmonary dysfunction, and upper-airway obstruction, identifying low-dose tiotropium as a potentially efficacious therapy, though benefit did not increase at the higher dose [25, 26]. A combination study found PaO2/FiO2 and airway pressures improved with tiotropium but showed no additive benefit from adding nebulized tPA ^[26]. Reviews consistently classify bronchodilators among adjuncts that still lack definitive efficacy evidence in inhalation injury ^[47].

Nebulized epinephrine

Nebulized epinephrine combines alpha-1 vasoconstriction, which reduces airway hyperemia and edema, with beta-2 bronchodilation, targeting the bronchial hyperemia and transvascular fluid flux of the injury ^[18]. The animal evidence is positive and fairly consistent. In ovine injury, 4 mg nebulized epinephrine every 4 hours significantly reduced tracheal and main-bronchial blood flows, ventilatory pressures, and lung malondialdehyde ^[18]. A separate ovine study found epinephrine significantly reduced pulmonary transvascular fluid flux to water and protein and reduced systemic fluid accumulation without considerable systemic effects ^[62]. In a head-to-head ovine comparison, nebulized epinephrine more effectively ameliorated injury severity than albuterol or phenylephrine, attributed to its combined alpha-1 and beta-2 properties ^[63]. In an ovine ECMO model, nebulized epinephrine improved oxygenation and reduced airway edema ^[76].

Human evidence is limited to safety and case use. A pediatric pilot randomized trial profiled the safety of nebulized racemic epinephrine added to standard care (NAC, heparin, albuterol) in severely burned children and found no adverse events and no attributable deaths, but it was not powered for efficacy ^[28]. No human efficacy trial of nebulized epinephrine exists in this setting; the positive efficacy story is entirely ovine, and that asymmetry between strong animal and near-absent human efficacy data is the honest characterization for this agent.

Systemic and adjunctive anticoagulants

Antithrombin is the systemic anticoagulant with the most human support. Antithrombin deficiency is common after burn and inhalation injury and was an independent predictor of length of stay and mortality ^[10]. In a non-randomized adult cohort, antithrombin (human) concentrate maintained plasma antithrombin levels, was associated with fewer pneumonia episodes (23% vs 43%, P < 0.01), and fewer ventilator days ^[58]. Antithrombin (human) concentrate has been tolerated in the pediatric acute phase ^[59]. In ovine models, recombinant human antithrombin reduced neutrophil trafficking, alveolar infiltration, edema, and airway obstruction, and attenuated vascular leakage and gas-exchange deterioration without increased bleeding [24, 64]. Despite this, no human randomized placebo-controlled trial has tested antithrombin's true benefit, and the literature explicitly calls for one ^[70].

Fibrinolytics are animal-only. Nebulized tissue plasminogen activator showed dose-dependent attenuation of pulmonary abnormalities in ovine injury, with cast clearance framed as crucial to managing burn-and-smoke ARDS ^[65]. Combination regimens carry interference and bleeding caveats: in triple therapy with intravenous antithrombin plus nebulized heparin and tPA, the anti-inflammatory effect of antithrombin alone was abolished, suggesting interference between anticoagulants ^[66]. Aerosolized tPA delivery is confounded by airway bleeding, which single-chain urokinase moderated in an ovine model ^[67].

For systemic venous-thromboembolism prophylaxis (distinct from airway-directed therapy), a large matched cohort of burn patients found prophylactic enoxaparin associated with lower 30-day mortality than unfractionated heparin (1.3% vs 3.6%) ^[74].

Corticosteroids

Corticosteroids are the central, unresolved controversy of this field, with an old, contradictory evidence base. The dominant modern position is no benefit. Methylprednisolone did not protect the lung in an ovine model ^[82]. A randomized trial of dexamethasone with aerosolized gentamicin found no difference in mortality, pulmonary complications, or pulmonary function ^[50]. A short-course steroid study found no additional pulmonary-function improvement in less-severe cases ^[54]. Guidelines and consensus panels do not recommend routine or prophylactic corticosteroids: prophylactic antibiotics and corticosteroids are not recommended in one evidence-based review, and prophylactic systemic corticosteroids were rated inappropriate by an international appropriateness panel [84, 71].

Positive signals persist but are historical, animal, transient, or single-case, and they keep the question alive rather than settling it. A newer ovine study of a dexamethasone-eluting endotracheal tube, intended to reduce inflammation, instead increased biofilm formation and elevated cytokines, a counterintuitive harm signal worth noting ^[72].

Antioxidants and emerging or experimental agents

This group is almost entirely preclinical; no agent here has stand-alone human efficacy evidence. Nebulized tocopherols (vitamin E) are the strongest single antioxidant signal, all ovine: gamma-tocopherol nebulization decreased oxidative stress, arginase activity, and collagen deposition and improved oxygenation after burn and smoke inhalation [35, 36]. Lazaroids, deferoxamine, and manganese superoxide dismutase are animal-only, and manganese superoxide dismutase failed to improve edema or gas exchange in ovine injury, limiting its clinical use ^[34].

Cell therapy is a large but preclinical literature with a critical burn-specific caveat. Mesenchymal stem cells home to injured lung and reduce inflammation through paracrine and macrophage-polarization mechanisms in animal models, and exosomes show similar effects [68, 69]. But in sheep with combined burn and smoke injury, mesenchymal stem cells did not attenuate pulmonary dysfunction, and skin burn diminished their benefit by promoting migration of cells away from the lung toward the burned skin ^[75]. Most positive cell-therapy data come from smoke-only models, so they should be read as future directions, not current practice.

Exogenous surfactant has small human case series showing physiologic improvement (compliance, oxygenation) but no demonstrated survival benefit, and it appears most useful as early therapy rather than salvage [93, 4]. Inhaled antibiotics, ceftazidime, and inhaled pulmonary vasodilators round out the adjunctive and special-exposure literature, largely as animal or short-term physiologic data ^[17].

Safety and complications

The predominant human bleeding signal for nebulized heparin is reassuring: studies report no clinically significant increase in bleeding risk and no derangement of coagulation parameters at 10,000 units [83, 53]. Antithrombin has been used in burns without increased bleeding ^[64].

Two non-bleeding harms are load-bearing. First, frequent nebulization carries an infection signal: a heparin/NAC/albuterol protocol significantly increased pneumonia (45% vs 11%, P = 0.03) without reducing mortality or ventilator days, prompting a call to minimize infection risk from frequent nebulized medications ^[41]. Other syntheses found pneumonia and reintubation rates not significantly different ^[37], so the signal is not uniform, but it is the strongest harm finding for the mainstay protocol. Second, a device-safety hazard: a nebulized-heparin trial encountered serious respiratory problems from saturation of the expiratory filter after nebulizations and was prematurely stopped for safety and feasibility, with blood-stained sputum and bleeding concerns being the most frequent reason to withhold nebulizations ^[60]. Agent-specific cautions include salbutamol-associated lactic acidosis, reported in a smoke-inhalation case in which lactate corrected on beta-agonist withdrawal and recurred on salbutamol reintroduction ^[86]. In a rat sulfur-mustard model, intratracheal heparin produced increased thrombin clotting times indicating systemic absorption, with increased red cells in lavage fluid in some animals, signaling a potential for intrapulmonary bleeding if used chronically ^[87].

Special considerations

The pediatric data are distinctive. The foundational pediatric study found an aerosolized heparin/NAC regimen associated with decreased reintubation, atelectasis, and mortality ^[21], and nebulized racemic epinephrine was profiled as safe in severely burned children ^[28]. Antithrombin (human) concentrate has been tolerated in the pediatric acute phase ^[59]. Pediatric pharmacokinetics and pharmacodynamics differ and affect agent choice and dosing.

The dominant special consideration is animal-to-human translation. There is an almost complete absence of high-quality human data, and most pharmacotherapy evidence is preclinical ^[6]. The combined burn-plus-smoke condition differs from isolated inhalation: it worsens morbidity and mortality, lowers plasma antithrombin further, and, for mesenchymal stem cells, abolishes a benefit seen in smoke-only models [6, 49, 75]. The Galveston ovine combined burn-and-smoke model underlies most of the consistent mechanistic data, which is precisely why the weak human translation is the recurring theme of this page.

Outcomes

Across human studies, mortality is the consistent null endpoint. The HIHI cohort showed ventilation and ventilator-free-day gains but no difference in 28-day mortality, lung-injury score, ventilator-associated pneumonia, or bleeding ^[27]. The dose-finding randomized trial improved lung-injury score and ventilation duration with no mortality or ICU length-of-stay benefit ^[53]. The 2025 early-heparin randomized trial improved physiologic and ventilation endpoints with comparable mortality ^[56]. The 2026 scheduled-bronchoscopy randomized trial lost its mortality signal on multivariable adjustment ^[78]. The recurring positive human endpoints are mechanical-ventilation duration, ventilator-free days, and lung-injury score, not survival. The pediatric heparin/NAC cohort remains the main historical mortality-benefit claim ^[21], and meta-analyses that pool a mortality risk ratio below 1 carry heavy quality warnings [80, 37]. Improvements in other aspects of burn care have not been mirrored in inhalation-injury outcomes, and the lack of uniform diagnostic criteria has kept mortality essentially unchanged for decades [89, 90].

Controversies and Evidence Gaps

• No large definitive RCT for the mainstay regimen. Calls for larger and multicenter trials of nebulized heparin and the heparin/NAC bundle are repeated across the literature [56, 73]. The most recent trials improved ventilator-free days and weaning but left mortality unchanged [56, 78], and a 2025 retrospective found no outcome improvement for grade II–III injuries ^[73].
• The steroid controversy is unresolved. Old human data are null and modern guidelines advise against routine or prophylactic use [50, 84, 71], yet historical animal benefit and modern salvage case reports keep the question open, and a dexamethasone-eluting endotracheal tube produced a harm signal ^[72].
• Protocol heterogeneity and no consensus. Unit guidelines vary substantially in agents and cut-offs, and an appropriateness panel split 74 appropriate, 40 uncertain, and 26 inappropriate across 140 statements [48, 71].
• Poor study quality across the anticoagulant literature. Pooled benefits may be biased by poor methodologic quality, and the evidence is judged weak or insufficient [80, 81].
• Preclinical-only signals awaiting human data. Cell therapy, exosomes, lazaroids, deferoxamine, tocopherols, fibrinolytics, and growth factors remain animal-only, and the burn-specific mesenchymal-stem-cell caveat shows model results may not transfer to patients [68, 75].
• Mortality has barely moved. Survival gains are attributed to general critical care rather than targeted agents, compounded by the absence of uniform diagnostic criteria [89, 44].
• Antithrombin awaits a definitive trial. No randomized placebo-controlled multicenter trial of antithrombin in burn trauma has been done ^[70].

References

[1] Jelenko C, Garrison AF, McKinley JC. "Respiratory problems complicating burn injury: recognition, assessment, and treatment." Postgraduate medicine 1975. PMID: 240158 https://pubmed.ncbi.nlm.nih.gov/240158/ [2] Cui P, et al. "Human amnion-derived mesenchymal stem cells alleviate lung injury induced by white smoke inhalation in rats." Stem cell research & therapy 2018. PMID: 29650044 https://pubmed.ncbi.nlm.nih.gov/29650044/ [3] Stone HH. "Pulmonary burns in children." Journal of pediatric surgery 1979. PMID: 423063 https://pubmed.ncbi.nlm.nih.gov/423063/ [4] Head JM. "Inhalation injury in burns." American journal of surgery 1980. PMID: 6892755 https://pubmed.ncbi.nlm.nih.gov/6892755/ [5] Brown M, Desai M, Traber LD, Herndon DN, Traber DL. "Dimethylsulfoxide with heparin in the treatment of smoke inhalation injury." The Journal of burn care & rehabilitation 1988. PMID: 3356738 https://pubmed.ncbi.nlm.nih.gov/3356738/ [6] Bartley AC, Edgar DW, Wood FM. "Pharmaco-management of inhalation injuries for burn survivors." Drug design, development and therapy 2009. PMID: 19920889 https://pubmed.ncbi.nlm.nih.gov/19920889/ [9] Cox CS, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN. "Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model." Surgery, gynecology & obstetrics 1993. PMID: 8460409 https://pubmed.ncbi.nlm.nih.gov/8460409/ [10] Niedermayr M, et al. "Antithrombin deficiency and its relationship to severe burns." Burns : journal of the International Society for Burn Injuries 2007. PMID: 17118562 https://pubmed.ncbi.nlm.nih.gov/17118562/ [11] Murakami K, et al. "Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep." Critical care medicine 2003. PMID: 12576969 https://pubmed.ncbi.nlm.nih.gov/12576969/ [12] Sterner JB, Zanders TB, Morris MJ, Cancio LC. "Inflammatory mediators in smoke inhalation injury." Inflammation & allergy drug targets 2009. PMID: 19275694 https://pubmed.ncbi.nlm.nih.gov/19275694/ [13] Palmieri TL, et al. "Continuous nebulized albuterol attenuates acute lung injury in an ovine model of combined burn and smoke inhalation." Critical care medicine 2006. PMID: 16607229 https://pubmed.ncbi.nlm.nih.gov/16607229/ [14] Murakami K, et al. "High-dose heparin fails to improve acute lung injury following smoke inhalation in sheep." Clinical science (London, England : 1979) 2003. PMID: 12653676 https://pubmed.ncbi.nlm.nih.gov/12653676/ [15] Cabrera A, Vargas MH, Ochoa LG, Escobedo G, Ashley-Sosa G, Rico-Méndez FG. "Spirometric changes in fire-eating subjects in Mexico City." Archives of medical research 2003. PMID: 12957523 https://pubmed.ncbi.nlm.nih.gov/12957523/ [16] Foncerrada G, et al. "Inhalation Injury in the Burned Patient." Annals of plastic surgery 2018. PMID: 29461292 https://pubmed.ncbi.nlm.nih.gov/29461292/ [17] Maybauer MO, et al. "Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock." Intensive care medicine 2007. PMID: 17503018 https://pubmed.ncbi.nlm.nih.gov/17503018/ [18] Lange M, et al. "Preclinical evaluation of epinephrine nebulization to reduce airway hyperemia and improve oxygenation after smoke inhalation injury." Critical care medicine 2011. PMID: 21263320 https://pubmed.ncbi.nlm.nih.gov/21263320/ [19] Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. "Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury." Journal of burn care & research : official publication of the American Burn Association 2009. PMID: 19165116 https://pubmed.ncbi.nlm.nih.gov/19165116/ [21] Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. "Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy." The Journal of burn care & rehabilitation 1998. PMID: 9622463 https://pubmed.ncbi.nlm.nih.gov/9622463/ [23] Jones SW, Williams FN, Cairns BA, Cartotto R. "Inhalation Injury: Pathophysiology, Diagnosis, and Treatment." Clinics in plastic surgery 2017. PMID: 28576239 https://pubmed.ncbi.nlm.nih.gov/28576239/ [24] Rehberg S, et al. "Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury." Critical care medicine 2013. PMID: 24107637 https://pubmed.ncbi.nlm.nih.gov/24107637/ [25] Jonkam C, et al. "Muscarinic receptor antagonist therapy improves acute pulmonary dysfunction after smoke inhalation injury in sheep." Critical care medicine 2010. PMID: 20838334 https://pubmed.ncbi.nlm.nih.gov/20838334/ [26] Jonkam C, et al. "Assessment of combined muscarinic antagonist and fibrinolytic therapy for inhalation injury." Journal of burn care & research : official publication of the American Burn Association 2012. PMID: 22210073 https://pubmed.ncbi.nlm.nih.gov/22210073/ [27] McIntire AM, et al. "Outcomes Following the Use of Nebulized Heparin for Inhalation Injury (HIHI Study)." Journal of burn care & research : official publication of the American Burn Association 2017. PMID: 27532613 https://pubmed.ncbi.nlm.nih.gov/27532613/ [28] Foncerrada G, et al. "Safety of Nebulized Epinephrine in Smoke Inhalation Injury." Journal of burn care & research : official publication of the American Burn Association 2017. PMID: 28570317 https://pubmed.ncbi.nlm.nih.gov/28570317/ [29] Zieliński M, Wróblewski P, Kozielski J. "Is inhaled heparin a viable therapeutic option in inhalation injury?." Advances in respiratory medicine 2019. PMID: 31282560 https://pubmed.ncbi.nlm.nih.gov/31282560/ [30] Enkhbaatar P, et al. "Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation." Critical care medicine 2007. PMID: 18074480 https://pubmed.ncbi.nlm.nih.gov/18074480/ [31] Glas GJ, et al. "HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial." Trials 2014. PMID: 24661817 https://pubmed.ncbi.nlm.nih.gov/24661817/ [34] Maybauer MO, et al. "Effects of manganese superoxide dismutase nebulization on pulmonary function in an ovine model of acute lung injury." Shock (Augusta, Ga.) 2005. PMID: 15665728 https://pubmed.ncbi.nlm.nih.gov/15665728/ [35] Yamamoto Y, et al. "γ-tocopherol nebulization decreases oxidative stress, arginase activity, and collagen deposition after burn and smoke inhalation in the ovine model." Shock (Augusta, Ga.) 2012. PMID: 23160521 https://pubmed.ncbi.nlm.nih.gov/23160521/ [36] Yamamoto Y, et al. "Nebulization with γ-tocopherol ameliorates acute lung injury after burn and smoke inhalation in the ovine model." Shock (Augusta, Ga.) 2012. PMID: 22266978 https://pubmed.ncbi.nlm.nih.gov/22266978/ [37] Lan X, Huang Z, Tan Z, Huang Z, Wang D, Huang Y. "Nebulized heparin for inhalation injury in burn patients: a systematic review and meta-analysis." Burns & trauma 2020. PMID: 32523966 https://pubmed.ncbi.nlm.nih.gov/32523966/ [38] Sang L, et al. "Protective Effect of Nebulized Heparin in the Animal Models of Smoke Inhalation Injury: A Meta-analysis and Systematic Review of Experimental Studies." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 36269755 https://pubmed.ncbi.nlm.nih.gov/36269755/ [40] McGinn KA, Weigartz K, Lintner A, Scalese MJ, Kahn SA. "Nebulized Heparin With N-Acetylcysteine and Albuterol Reduces Duration of Mechanical Ventilation in Patients With Inhalation Injury." Journal of pharmacy practice 2019. PMID: 29233052 https://pubmed.ncbi.nlm.nih.gov/29233052/ [41] Kashefi NS, Nathan JI, Dissanaike S. "Does a Nebulized Heparin/N-acetylcysteine Protocol Improve Outcomes in Adult Smoke Inhalation?." Plastic and reconstructive surgery. Global open 2014. PMID: 25289358 https://pubmed.ncbi.nlm.nih.gov/25289358/ [42] Elsharnouby NM, Eid HE, Abou Elezz NF, Aboelatta YA. "Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury: a study of different doses." Journal of critical care 2014. PMID: 23932140 https://pubmed.ncbi.nlm.nih.gov/23932140/ [44] Dries DJ, Endorf FW. "Inhalation injury: epidemiology, pathology, treatment strategies." Scandinavian journal of trauma, resuscitation and emergency medicine 2013. PMID: 23597126 https://pubmed.ncbi.nlm.nih.gov/23597126/ [45] Guo B, et al. "Preclinical and clinical studies of smoke-inhalation-induced acute lung injury: update on both pathogenesis and innovative therapy." Therapeutic advances in respiratory disease 2019. PMID: 31068086 https://pubmed.ncbi.nlm.nih.gov/31068086/ [47] Walker PF, et al. "Diagnosis and management of inhalation injury: an updated review." Critical care (London, England) 2015. PMID: 26507130 https://pubmed.ncbi.nlm.nih.gov/26507130/ [48] Rajaratnam G, Baldwin AJ. "'To BAL or not to BAL, that is the question': Variations in smoke inhalation injury guidelines from burn units and centres in England, Scotland and Wales." Burns : journal of the International Society for Burn Injuries 2024. PMID: 39353794 https://pubmed.ncbi.nlm.nih.gov/39353794/ [49] Kowal-Vern A, Dennis AJ, Bourdon P, Casey LE, Latenser BA. "Bronchoalveolar lavage and plasma Antithrombin and cytokines in inhalation and burn injury: a pilot study." International journal of burns and trauma 2020. PMID: 33224614 https://pubmed.ncbi.nlm.nih.gov/33224614/ [50] Levine BA, Petroff PA, Slade CL, Pruitt BA. "Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient." The Journal of trauma 1978. PMID: 347099 https://pubmed.ncbi.nlm.nih.gov/347099/ [53] Elsharnouby NM, Eid HE, Abou Elezz NF, Aboelatta YA. "Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury: a study of different doses." Journal of critical care 2014. PMID: 23932140 https://pubmed.ncbi.nlm.nih.gov/23932140/ [54] Cha SI, et al. "Isolated smoke inhalation injuries: acute respiratory dysfunction, clinical outcomes, and short-term evolution of pulmonary functions with the effects of steroids." Burns : journal of the International Society for Burn Injuries 2007. PMID: 17169496 https://pubmed.ncbi.nlm.nih.gov/17169496/ [55] Elsharnouby NM, Eid HE, Abou Elezz NF, Aboelatta YA. "Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury: a study of different doses." Journal of critical care 2014. PMID: 23932140 https://pubmed.ncbi.nlm.nih.gov/23932140/ [56] Hakim SM, Fouad MN, Habib MK, Mohamed MS, Ghaly SI. "Effect of early administration of inhaled heparin on outcomes of smoke inhalation injury: A randomized controlled trial." Burns : journal of the International Society for Burn Injuries 2025. PMID: 40319829 https://pubmed.ncbi.nlm.nih.gov/40319829/ [58] Kowal-Vern A, Walenga JM, McGill V, Gamelli RL. "The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury." Burns : journal of the International Society for Burn Injuries 2001. PMID: 11164666 https://pubmed.ncbi.nlm.nih.gov/11164666/ [59] Kowal-Vern A, Latenser BA. "Antithrombin (human) concentrate infusion in pediatric patients with >50% TBSA burns." Burns : journal of the International Society for Burn Injuries 2003. PMID: 12927992 https://pubmed.ncbi.nlm.nih.gov/12927992/ [60] Glas GJ, et al. "Nebulized Heparin in Burn Patients with Inhalation Trauma-Safety and Feasibility." Journal of clinical medicine 2020. PMID: 32218127 https://pubmed.ncbi.nlm.nih.gov/32218127/ [62] Lopez E, et al. "Nebulized Epinephrine Limits Pulmonary Vascular Hyperpermeability to Water and Protein in Ovine With Burn and Smoke Inhalation Injury." Critical care medicine 2016. PMID: 26465218 https://pubmed.ncbi.nlm.nih.gov/26465218/ [63] Fukuda S, et al. "Superior Effects of Nebulized Epinephrine to Nebulized Albuterol and Phenylephrine in Burn and Smoke Inhalation-Induced Acute Lung Injury." Shock (Augusta, Ga.) 2020. PMID: 32590700 https://pubmed.ncbi.nlm.nih.gov/32590700/ [64] Rehberg S, et al. "Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury." Critical care medicine 2013. PMID: 24107637 https://pubmed.ncbi.nlm.nih.gov/24107637/ [65] Enkhbaatar P, et al. "Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation." Shock (Augusta, Ga.) 2004. PMID: 15201705 https://pubmed.ncbi.nlm.nih.gov/15201705/ [66] Rehberg S, et al. "Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome." The journal of trauma and acute care surgery 2014. PMID: 24368367 https://pubmed.ncbi.nlm.nih.gov/24368367/ [67] Wolfson MR, et al. "Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury." Clinical and translational medicine 2020. PMID: 32508014 https://pubmed.ncbi.nlm.nih.gov/32508014/ [68] Guo X, et al. "Bone marrow mesenchymal stromal cells attenuate smoke inhalation injury by regulating the M1/M2-Th17/Treg immune homeostasis axis." International immunopharmacology 2024. PMID: 39182266 https://pubmed.ncbi.nlm.nih.gov/39182266/ [69] Xu B, Gan CX, Chen SS, Li JQ, Liu MZ, Guo GH. "BMSC-derived exosomes alleviate smoke inhalation lung injury through blockade of the HMGB1/NF-κB pathway." Life sciences 2020. PMID: 32621926 https://pubmed.ncbi.nlm.nih.gov/32621926/ [70] Kowal-Vern A, Orkin BA. "Antithrombin in the treatment of burn trauma." World journal of critical care medicine 2016. PMID: 26855890 https://pubmed.ncbi.nlm.nih.gov/26855890/ [71] Milton-Jones H, et al. "An international RAND/UCLA expert panel to determine the optimal diagnosis and management of burn inhalation injury." Critical care (London, England) 2023. PMID: 38012797 https://pubmed.ncbi.nlm.nih.gov/38012797/ [72] Gonzales G, Malka R, Bizios R, Dion GR, Guda T. "Burn inhalation injury and intubation with dexamethasone-eluting endotracheal tubes modulate local microbiome and alter airway inflammation." Frontiers in bioengineering and biotechnology 2025. PMID: 40078791 https://pubmed.ncbi.nlm.nih.gov/40078791/ [73] Risinger WB, et al. "Nebulized Heparin and N-Acetylcysteine do Not Improve Outcomes of Intubated Burn Patients With Grade II or III Inhalation Injuries." The American surgeon 2025. PMID: 40346841 https://pubmed.ncbi.nlm.nih.gov/40346841/ [74] Patel MM, et al. "Impact of Heparin and Enoxaparin Anticoagulant Prophylaxis on Improving Acute Mortality in Burn Patients." Journal of burn care & research : official publication of the American Burn Association 2026. PMID: 40355368 https://pubmed.ncbi.nlm.nih.gov/40355368/ [75] Baljinnyam T, Radnaa E, Niimi Y, Fukuda S, Prough DS, Enkhbaatar P. "Cutaneous burn diminishes beneficial effect of intravenously administered mesenchymal stem cells on acute lung injury induced by smoke inhalation in sheep." Burns : journal of the International Society for Burn Injuries 2020. PMID: 32513501 https://pubmed.ncbi.nlm.nih.gov/32513501/ [76] Kakizaki R, Nakamoto K, Batsaikhan TA, Enkhbaatar P. "Nebulized Epinephrine Improves Oxygenation During Extracorporeal Membrane Oxygenation in Sheep with Smoke Inhalation-Induced Acute Respiratory Distress Syndrome." Shock (Augusta, Ga.) 2025. PMID: 41165743 https://pubmed.ncbi.nlm.nih.gov/41165743/ [78] Nguyen TNM, Nguyen NL, Tran DH. "Scheduled Bronchoscopy with Nebulized Heparin and N-Acetylcysteine in Burn Patients with Inhalation Injury: A Randomized Trial." European burn journal 2026. PMID: 42201099 https://pubmed.ncbi.nlm.nih.gov/42201099/ [80] Oremus M, et al. "A systematic review of heparin to treat burn injury." Journal of burn care & research : official publication of the American Burn Association 2007. PMID: 17925636 https://pubmed.ncbi.nlm.nih.gov/17925636/ [81] Oremus M, et al. "The uses of heparin to treat burn injury." Evidence report/technology assessment 2006. PMID: 17764219 https://pubmed.ncbi.nlm.nih.gov/17764219/ [82] Nieman GF, Clark WR, Hakim T. "Methylprednisolone does not protect the lung from inhalation injury." Burns : journal of the International Society for Burn Injuries 1991. PMID: 1760107 https://pubmed.ncbi.nlm.nih.gov/1760107/ [83] Yip LY, Lim YF, Chan HN. "Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre." Burns : journal of the International Society for Burn Injuries 2011. PMID: 21816542 https://pubmed.ncbi.nlm.nih.gov/21816542/ [84] Deutsch CJ, Tan A, Smailes S, Dziewulski P. "The diagnosis and management of inhalation injury: An evidence based approach." Burns : journal of the International Society for Burn Injuries 2018. PMID: 29398078 https://pubmed.ncbi.nlm.nih.gov/29398078/ [85] Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ. "Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations." Critical care (London, England) 2012. PMID: 22546487 https://pubmed.ncbi.nlm.nih.gov/22546487/ [86] Taboulet P, Clemessy JL, Freminet A, Baud FJ. "A case of life-threatening lactic acidosis after smoke inhalation - interference between beta-adrenergic agents and ethanol?." Intensive care medicine 1995. PMID: 8750132 https://pubmed.ncbi.nlm.nih.gov/8750132/ [87] Houin PR, et al. "Intratracheal heparin improves plastic bronchitis due to sulfur mustard analog." Pediatric pulmonology 2015. PMID: 24692161 https://pubmed.ncbi.nlm.nih.gov/24692161/ [88] Tasaki O, Mozingo DW, Dubick MA, Goodwin CW, Yantis LD, Pruitt BA. "Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model." Critical care medicine 2002. PMID: 11998809 https://pubmed.ncbi.nlm.nih.gov/11998809/ [89] Rehberg S, Maybauer MO, Enkhbaatar P, Maybauer DM, Yamamoto Y, Traber DL. "Pathophysiology, management and treatment of smoke inhalation injury." Expert review of respiratory medicine 2009. PMID: 20161170 https://pubmed.ncbi.nlm.nih.gov/20161170/ [90] Toon MH, Maybauer MO, Greenwood JE, Maybauer DM, Fraser JF. "Management of acute smoke inhalation injury." Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine 2010. PMID: 20196715 https://pubmed.ncbi.nlm.nih.gov/20196715/ [91] Phelps MK, Olson LM, Patel MAVB, Thompson MJ, Murphy CV. "Nebulized Heparin for Adult Patients With Smoke Inhalation Injury: A Review of the Literature." The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2020. PMID: 34752548 https://pubmed.ncbi.nlm.nih.gov/34752548/ [92] Feldbaum DM, Wormuth D, Nieman GF, Paskanik M, Clark WR, Hakim TS. "Exosurf treatment following wood smoke inhalation." Burns : journal of the International Society for Burn Injuries 1993. PMID: 8216766 https://pubmed.ncbi.nlm.nih.gov/8216766/ [93] Tortorolo L, Chiaretti A, Piastra M, Viola L, Polidori G. "Surfactant treatment in a pediatric burn patient with respiratory failure." Pediatric emergency care 1999. PMID: 10608328 https://pubmed.ncbi.nlm.nih.gov/10608328/ [94] Ashraf U, Bajantri B, Roa-Gomez G, Venkatram S, Cantin A, Diaz-Fuentes G. "Nebulized heparin and N-acetylcysteine for smoke inhalational injury: A case report." Medicine 2018. PMID: 29742703 https://pubmed.ncbi.nlm.nih.gov/29742703/